RPL17 and neoplasm: Blocking these receptors (e.g., PD-1 and CTLA-4) reverses the state and reactivates the immune response, thereby halting tumor progression 12, 41-44 which demonstrates the great potential of immune checkpoint blockade therapies in this regard.